Search research articles
Contact Us
Filters
Showing results (131-140 of 1,123) with videos related to
Page
of 113
Sort By:
The New England Journal of Medicine
|
October 4, 2018
Enzalutamide in Castration-Resistant Prostate Cancer
Maha Hussain, Fred Saad, Cora N Sternberg
Nature Reviews. Urology
|
May 18, 2021
Treatment and trials in non-metastatic castration-resistant prostate cancer
Soum D Lokeshwar, Zachary Klaassen, Fred Saad
Expert Opinion on Drug Safety
|
June 11, 2021
A drug safety evaluation of enzalutamide to treat advanced prostate cancer
Fred Saad, Zineb Hamilou, Jean-Baptiste Lattouf
Current Opinion in Supportive and Palliative Care
|
June 26, 2009
Predicting life expectancy in prostate cancer patients
Claudio Jeldres, Jean-Baptiste Latouff, Fred Saad
Current Opinion in Supportive and Palliative Care
|
August 10, 2011
Penile cancer: what's new?
Julien Letendre, Fred Saad, Jean-Baptiste Lattouf
Urologic Oncology
|
December 18, 2010
Biochemical markers of bone turnover and clinical outcomes in men with prostate cancer
Fred Saad, James A Eastham, Matthew R Smith
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada
|
January 4, 2013
Management of skeletal-related events in patients with advanced prostate cancer and bone metastases: Incorporating new agents into clinical practice
Alan So, Joseph Chin, Neil Fleshner, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada
|
February 6, 2019
Canadian Urological Association Best Practice Report: Diagnosis and management of radiation-induced hemorrhagic cystitis
George Goucher, Fred Saad, Himu Lukka, et al.
Prostate Cancer and Prostatic Diseases
|
February 9, 2021
Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors
Fred Saad, Martin Bögemann, Kazuhiro Suzuki, et al.
European Urology
|
December 2, 2023
Reply to Lin Ding, Bin Yang, and Xudong Yao's Letter to the Editor re: Fred Saad, Noel W. Clarke, Mototsugu Oya, et al. Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Metastatic Castration-resistant Prostate Cancer (PROpel): Final Prespecified Overall Survival Results of a Randomised, Double-blind, Phase 3 Trial. Lancet Oncol 2023;24:1094-108
Fred Saad, Paula Del Rosario, Noel W Clarke
Page
of 113
Search research articles
Search
Showing results (131-140 of 1,123) with videos related to
Sort By:
Page
of 113
The New England Journal of Medicine
|
October 4, 2018
Enzalutamide in Castration-Resistant Prostate Cancer
Maha Hussain, Fred Saad, Cora N Sternberg
Nature Reviews. Urology
|
May 18, 2021
Treatment and trials in non-metastatic castration-resistant prostate cancer
Soum D Lokeshwar, Zachary Klaassen, Fred Saad
Expert Opinion on Drug Safety
|
June 11, 2021
A drug safety evaluation of enzalutamide to treat advanced prostate cancer
Fred Saad, Zineb Hamilou, Jean-Baptiste Lattouf
Current Opinion in Supportive and Palliative Care
|
June 26, 2009
Predicting life expectancy in prostate cancer patients
Claudio Jeldres, Jean-Baptiste Latouff, Fred Saad
Current Opinion in Supportive and Palliative Care
|
August 10, 2011
Penile cancer: what's new?
Julien Letendre, Fred Saad, Jean-Baptiste Lattouf
Urologic Oncology
|
December 18, 2010
Biochemical markers of bone turnover and clinical outcomes in men with prostate cancer
Fred Saad, James A Eastham, Matthew R Smith
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada
|
January 4, 2013
Management of skeletal-related events in patients with advanced prostate cancer and bone metastases: Incorporating new agents into clinical practice
Alan So, Joseph Chin, Neil Fleshner, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada
|
February 6, 2019
Canadian Urological Association Best Practice Report: Diagnosis and management of radiation-induced hemorrhagic cystitis
George Goucher, Fred Saad, Himu Lukka, et al.
Prostate Cancer and Prostatic Diseases
|
February 9, 2021
Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors
Fred Saad, Martin Bögemann, Kazuhiro Suzuki, et al.
European Urology
|
December 2, 2023
Reply to Lin Ding, Bin Yang, and Xudong Yao's Letter to the Editor re: Fred Saad, Noel W. Clarke, Mototsugu Oya, et al. Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Metastatic Castration-resistant Prostate Cancer (PROpel): Final Prespecified Overall Survival Results of a Randomised, Double-blind, Phase 3 Trial. Lancet Oncol 2023;24:1094-108
Fred Saad, Paula Del Rosario, Noel W Clarke
Page
of 113